Haleon plc (HLN)
| Previous close | 8.32 |
| Open | 8.39 |
| Bid | 8.33 x 27000 |
| Ask | 8.34 x 21500 |
| Day's range | 8.31 - 8.40 |
| 52-week range | 7.70 - 8.98 |
| Volume | |
| Avg. volume | 5,863,524 |
| Market cap | 38.082B |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | 28.76 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 0.21 (2.56%) |
| Ex-dividend date | 14 Mar 2024 |
| 1y target est | N/A |
- Simply Wall St.
With 54% ownership of the shares, Haleon plc (LON:HLN) is heavily dominated by institutional owners
Key Insights Significantly high institutional ownership implies Haleon's stock price is sensitive to their trading...
- Insider Monkey
Haleon plc (NYSE:HLN) Q1 2024 Earnings Call Transcript
Haleon plc (NYSE:HLN) Q1 2024 Earnings Call Transcript May 2, 2024 Haleon plc isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Ladies and gentlemen, welcome to the Haleon Q1 2024 Trading Update Conference Call. I am Davin, the chorus call […]
- Reuters
UPDATE 2-Sensodyne-maker Haleon posts tepid sales as demand for some products cool off
Consumer healthcare company Haleon reported first-quarter revenue slightly below market estimates on Wednesday, as volumes declined due to retailer destocking in U.S. and cooling demand for some of its medicines after a surge last year. The maker of popular household products such as Sensodyne toothpaste and pain-reliever Panadol, had earlier said that the first three months of 2024 would be impacted by a softer cold and flu season and a slowdown in painkiller Advil's sales in Canada, following a surge in demand last year. Demand for medicines such as Contac and Fenbid, which benefited from pent-up demand in China last year after lockdown restrictions were lifted, have also cooled, impacting Haleon's quarterly sales growth.
